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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy that often presents clinically at 
an advanced stage and that may be confused with chronic pancreatitis (CP). Conversely, CP may 
be misdiagnosed as PDAC leading to unwarranted pancreas resection. Therefore, early PDAC 
diagnosis and clear differentiation between PDAC and CP are crucial for improved care. 
Exosomes are circulating micro-vesicles whose components can serve as cancer biomarkers. We 
compared exosomal glypican-1 (GPC1) and microRNA levels in normal control subjects and in 
patients with PDAC and CP. We report that exosomal GPC1 is not diagnostic for PDAC, whereas 
high exosomal levels of microRNA-10b, (miR-10b), miR-21, miR-30c, and miR-181a and low 
miR-let7a readily differentiate PDAC from normal control and CP samples. By contrast with 
GPC1, elevated exosomal miR levels decreased to normal values within 24 h following PDAC 
resection. All 29 PDAC cases exhibited significantly elevated exosomal miR-10b and miR-30c 
levels, whereas 8 cases had normal or slightly increased CA 19-9 levels. Thus, our exosomal miR 
signature is superior to exosomal GPC1 or plasma CA 19-9 levels in establishing a diagnosis of 
PDAC and differentiating between PDAC and CP.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy characterized by an 
abundant stroma, marked resistance to chemotherapy and radiotherapy, and advanced stage 
at clinical presentation precluding resection in 80% of patients [1,2]. Consequently, the 5-
year survival rate is only 9% [3]. Moreover, PDAC is currently the third leading cause of 
cancer death in the United States, and is projected to become the second leading cause of 
cancer death by 2020 [3,4]. There is an urgent need, therefore, to devise strategies for early 
PDAC detection to allow for the potential of a surgical cure. This has been an elusive goal 
due to the absence of sufficiently specific and sensitive biomarkers.
Heparan sulfate proteoglycans (HSPGs) are ubiquitous macromolecules that are found on 
cell surfaces and in the extracellular matrix [5]. They consist of core proteins to which are 
covalently attached glycosaminoglycans (GAGs) polysaccharide chains that are variable in 
size and type. GAGs consist of disaccharide repeats, most often of D-glucuronic or L-
iduronic acid and either N-acetylglucosamine or N-acetylgalactosamine [5,6]. GAGs exhibit 
marked diversity due to variations in the disaccharides and sites of sulfation [6]. In addition 
to heparin and heparan sulfate (HS), GAGs may consist of keratan, chondroitin or dermatan 
sulfates, and hyaluronan [6,7]. Two families of HSPGs, glypicans and syndecans, carry the 
majority of the HS on mammalian cells [8–10]. There are six glypican genes encoding 
glypican proteins, which are attached to the plasma membrane via glycophosphatidyl 
inositol anchors, and four syndecan genes encoding four transmembrane proteins [8–10].
We previously reported that glypican-1 (GPC1) expression (but not other glypicans) is 
upregulated in PDAC, and that heparin-binding growth factors require its presence on 
pancreatic cancer cell (PCC) membranes in order to enhance proliferation and migration 
[11]. We also reported that high GPC1 levels promote angiogenesis and metastasis in an 
orthotopic mouse model of PDAC [12], and that in an oncogenic KRAS-driven genetically 
engineered mouse model of PDAC in which the Ink4a locus has been deleted, the absence of 
GPC1 is associated with attenuated angiogenesis and tumor growth [13].
HSPGs such as glypicans and syndecans can also act as receptors that internalize exosomes 
[14]. Conversely, during the internalization process, HSPGs are taken up by exosomes [14]. 
Recently, exosome-associated GPC1 has been reported as a highly specific and sensitive 
biomarker for early PDAC detection [15]. Further validation of this observation is required 
since highly specific anti-GPC1 antibodies are not readily available.
MicroRNAs (miRs) are small, non-coding RNAs that are highly conserved and that 
modulate developmental, physiological and pathological cellular processes by repressing 
mRNA translation [16,17]. In addition, miRs exert crucial roles in numerous cancers [18–
20]. Due to their marked stability miRs may serve as diagnostic biomarkers in the systemic 
circulation [21]. Moreover, miRs are present in circulating exosomes where they remain 
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stable under appropriate storage conditions [22,23]. By in situ hybridization using highly 
specific locked nucleic acid probes, we previously reported that miR-10b and miR-21 are 
abundant in the cancer cells in PDAC [24,25]. We subsequently showed that miRs are 
present in the circulation, and that high plasma miR-10b levels are seen in patients with 
PDAC but not in patients with chronic pancreatitis (CP) or in normal controls [26].
We now describe a method to quantitatively analyze exosomal GPC1 by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). Using the peptide QIYGAK that 
is unique for GPC1 and is not shared with glypican-2, -3, -4, -5, or -6 or with other human 
proteins, we demonstrate that this novel method is rapid, sensitive, and robust, enabling 
efficient high-throughput analysis of clinical samples. Using exosomes prepared from the 
plasma of individuals without pancreatic disease and from patients with PDAC and CP prior 
to and following pancreas resection, we compared the levels of GPC1, miR-10b, -21, -30c, 
-106b, -181a, -483, -20, -let7a, and -122a and assessed their utility as potential PDAC 
biomarkers. GPC1 levels were relatively similar in exosomes derived from normal controls, 
and patients with PDAC or CP. By contrast, exosomal levels of miR-10b, -20a, -21, -30c, 
-106b, and -181a were significantly higher in PDAC by comparison with corresponding 
control and CP levels, and the elevated levels of all six miRs normalized following PDAC 
resection, whereas the levels of exosomal GPC1 were only slightly lower post-resection.
Materials and methods
Materials
Light peptide QIYGAK (LG021) was purchased from Peptide 2.0 Inc. (Chantilly, VA, 
USA). Isotopically labeled heavy peptide QIYGAK* (Lysine, 13C6, 15N2) (HG021) used as 
an internal standard was obtained from New England Peptide Inc. (Gardner, MA, USA). 
Bovine serum albumin (BSA) was purchased from Sigma–Aldrich (St. Louis, MO, USA). 
Phosphate Buffered Saline (PBS-1X) was obtained from Lonza (Allendale, NJ). High 
pressure liquid chromatography HPLC grade water (H2O), acetonitrile (ACN), 0.1% formic 
acid in ACN, and 0.1% formic acid in water (H2O) were all purchased from Burdick & 
Jackson (Muskegon, MI, USA).
Patient samples
Individuals with PDAC were treatment-naïve prior to undergoing resection, and the 
diagnosis of PDAC required cytopathological confirmation. Individuals with CP were 
classified by the Cambridge criteria [27,28] based on endoscopic retrograde 
cholangiopancreatography (ERCP). Control subjects had previously undergone normal cross 
sectional imaging of the pancreas as part of an evaluation of abdominal symptoms that did 
not reveal the presence of cancer. Prior to subject enrollment, the Indiana University 
Institutional Review Board approved this study protocol and each subject signed informed 
consent. Blood (10–20 ml) was collected into EDTA-coated tubes prior to surgery and 
approximately 24 h following surgery for all patients with PDAC (n = 29) or CP (n = 11), 
and during a clinic visit in the case of the six control subjects. Specimens were promptly 
placed on ice or in a refrigerator (4°C), taken to the lab and rapidly processed by 
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centrifugation (1000 × g for 10 min) at 4°C (within 1 h of collection). Plasma supernatants 
were collected and stored at −8°C until analysis.
We analyzed GPC1 levels in exosomes from the plasma of six normal control subjects who 
did not have pancreatic disease, as well as from pre-operative and post-operative exosomes 
from 3 patients with CP and from 3 patients with PDAC. To prepare exosomes, plasma 
samples were thawed on ice and centrifuged at 10,000 × g for 30 min at 4 °C. Supernatants 
were filtered through a 0.22 mm filter using a syringe and the filtrate (250 μL) was 
centrifuged twice at 110,000 × g for 2 h (4 °C) with an intervening PBS wash [29]. 
Exosomes were suspended in 100 μL of 1 M Tris (pH 7.4) for analysis. An aliquot of the 
exosome-rich solution was diluted 1:10 in PBS for diameter and concentration quantitation, 
utilizing the qNano system and the NP100 nanopore, both from Izon Science (Cambridge, 
MA), under optimized principles of tunable resistive pulse sensing (RSP) as provided by 
Izon Science [30,31].
The diameter of the vast majority of normal control exosomes ranged from 60 to 100 nm 
(Supplemental Fig. S1), whereas the diameter of CP (Supplemental Fig. S2) and PDAC 
exosomes ranged from 70 to 120 nm (Supplemental Fig. S3). Importantly, the smallest 
exosomes were at the lowest limit of detection by RSP. Exosome purity was confirmed by 
standard electron microscopy (EM) (Supplemental Fig. S4). The diameter of the majority of 
exosomes ranged from 54 to 64 nm, which is consistent with imaging by this method due to 
surface adherence, and changes caused by adherence, fixation and dessication [29,30]. For 
immunoblotting, exosomes were suspended in exosome lysis buffer [15] and Western 
blotting was performed [32] with an anti-CD63 antibody (Santa Cruz). As expected, 
exosomes expressed the exosomal marker CD63 (Supplemental Fig. S5).
Preparation of standards and quality control samples for LC-MS/MS
A stock standard solution of LG021 (“light”, non-labeled analyte) was prepared at a 
concentration of 30 mM using the appropriate weight for lot purity correction and 50% 
acetonitrile (ACN) in water with 0.1% formic acid. Duplicate solutions (Set 1 and Set 2) 
were compared before they were used for preparing intermediate standard solutions. The 
intermediate standard solutions of LG021 were prepared from Set 1 of the serial dilution 
stock standard solutions at concentrations of 3.0, 2.4, 1.2, 0.96, 0.48, 0.24, 0.12, and 0.06 
μM for the preparation of calibration curves. Intermediate quality control (QC) standard 
solutions of LG021 were prepared from Set 2 of the serial dilution stock standard solutions 
at concentrations of 1.5, 0.6, 0.3, and 0.06 μM for the preparation of quality controls, using 
HPLC grade water with 0.1% formic acid by dilution from the stock standard solutions. The 
calibration standard samples of LG021 were prepared by spiking the corresponding 
intermediate calibration standard solutions of 3.0, 2.4, 1.2, 0.96, 0.48, 0.24, 0.12, and 0.06 
μM, respectively, into digested BSA to provide concentrations of 0.50, 0.40, 0.02, 0.16, 0.08, 
0.04, 0.02, and 0.01 μM, respectively. The QC standard samples of LG021 were prepared at 
concentrations of 0.25, 0.10, 0.05, and 0.01 μM, by spiking digested BSA with the 
intermediate QC standard solutions.
In addition to the above, a stock internal standard solution of HG021 (“heavy”, stable-
isotope labeled analyte) was prepared at a concentration of 30 mM using the appropriate 
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weight for lot purity correction and 50% ACN in water with 0.1% formic acid. Working 
internal standard solutions were prepared from the stock internal standard solution at a 
concentration of 0.75 μM.
Sample preparation and chromatographic conditions for LC-MS/MS
Samples were prepared as follows: 50 μL of each sample (1% BSA and clinical patient 
samples) were dried in a Speed-vac for 1 h and reconstituted with 50 μL of 8 M urea. 
Dithiothreitol (50 μL of 10 mM stock solution) was added to reduce disulfide bonds. The 
mixture was then incubated at 60 °C for 60 min prior to adding 50 μL of 55 mM 
iodoacetamide in 100 mM NH4HCO3. The mixture was then incubated in the dark for 60 
min (room temperature), followed by the addition of trypsin (50 μL of 0.1 μg/μL stock 
solution) to digest the proteins and an 18 h incubation at 37 °C.
After the tryptic digestion, 60 μL of each patient sample were spiked with 10 μL of 0.75 μM 
internal standard; 50 μL of each calibration standard and QC sample were spiked with 10 μL 
of each intermediate calibration standard solution and 10 μL of 0.75 μM internal standard. 
Each sample was mixed, cleaned up with C18 Silica Macro Spincolumns (Fisher Scientific, 
Waltham, MA, Cat. #: NC9840653), filtered with Ultrafree-MC centrifugal filter units with 
microporous membrane (Millipore, Billerica, MA, Cat. #: UFC30GVNB), transferred to a 
vial, and prepared for mass spec analysis.
A Dionex Ultimate 3000 UHPLC system (Sunnyvale, CA) consisting of a dual pump, 
autosampler, column oven, and a UV detector was used for peptide separation. A SCIEX 
4000 QTRAP triple quadrupole mass spectrometer (Toronto, Canada) with a TurboIonSpray 
probe was used in positive ion mode for multiple reaction monitoring (MRM). SCIEX 
Analyst 1.5 was used for data collection and SCIEX MultiQuant v3.0.1 was used for peak 
integration and peptide concentration calculation.
HPLC separation was performed on a Waters XBridge BEH C8 XP Column (2.1 × 100 mm, 
2.6 μm) (Cat. #: 186006043, Milford, MA) at 35 °C. The mobile phase A was 0.1% formic 
acid in water and the mobile phase B was 0.1% formic acid in ACN. The gradient was 0.0–
1.6 min, 5% B; 1.6–1.61 min, gradient to 16% B; 1.6–4.0 min, gradient to 25% B; 4.0–4.7 
min, gradient to 80% B; 4.7–5.3 min, 80% B; and 5.4–7.0 min, 5% B. The flow rate was set 
at 0.3 ml/min and the injection volume was 10 μL.
MS/MS detection and validation procedure
Scheduled MRM (sMRM) transitions monitored for each analyte (precursor ion/ product ion 
in m/z) were: LG021, 340.2/275.2 at retention time (RT) 3.30 min; HG021, 344.2/283.2 at 
RT 3.30 min. Ionization source and shared compound parameters were as follows: CUR, 40; 
CAD, 7; IS, 5500; TEM, 500; GS1, 50; and GS2, 50. DP, EP, CE, and CXP were 
57/10/19.5/14, and 57/7/20/14 for LG021 and HG021, respectively.
Validations were performed according to the Guidance for Industry: Bioanalytical Methods 
Validation issued (May 2001) by the U.S. Department of Health and Human Services, the 
Food and Drug Administration, and the Centers for Drug Evaluation and Research and for 
Veterinary Medicine (http://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf). 
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Calibration curves and linearity, intra-assay and inter-assay precision and accuracy, 
selectivity, matrix effect, spike-recovery, and stability were performed as described in our 
previous publication [33].
Reverse-transcriptase quantitative PCR
Total exosomal RNA was isolated using Trizol-LS (Life Technologies, Carlsbad, CA, USA) 
and Direct-zol RNA MiniPrep kit (Zymo Research). cDNA was generated using 10 ng of 
RNA per reaction for miR-10b, -20a, -21, -30c, -106b, -122, -181a, -483, -let7a, and -425-5p 
RT primers and a miR reverse transcription kit (Life Technologies), as previously reported 
[26]. Reverse transcriptase quantitative PCR (RT-qPCR) was performed in duplicate for each 
miR using the corresponding miR Taqman® probes and TaqMan Fast Advanced Master 
Mix. Expression was normalized to miR-425-5p, and the ΔCt values for miRNAs in 6 
control samples were averaged and subtracted from the ΔCt values of each sample, yielding 
a ΔΔCt value. The levels of each miRNA were calculated using the 2−ΔΔCt method [34].
CA 19-9 assay
CA 19-9 is the only FDA-approved biomarker for PDAC management. To compare the 
utility of exosomal miR levels with CA19-9 levels in establishing the diagnosis of PDAC, 
plasma CA19-9 was measured in duplicate by ELISA using CA19-9 AccuBind ELISA 
Microwells (Monobind Inc, Lake Forest, CA) according to the manufacturer’s instructions.
Statistics
Single-factor ANOVA was performed for RT-qPCR and LC-MS/MS data analysis, followed 
by Bonferroni adjustment. When indicated, paired t-tests were performed to compare pre- 
and post-surgery values. In addition, predictive performance was assessed using the Receiver 
Operating Characteristic (ROC) and the area under the curve (AUC). Excellent accuracy was 
defined as AUC>0.90.
Results
MS/MS detection
The molecular weight of the two standards, LG021 (MW: 678.4) and HG021 (MW: 686.4), 
has a difference of 8 Da. Their precursor ion (2+, 340.2 vs. 344.2) mass has a difference of 4 
Da. Their unique product ion (1+, 275.2 vs. 283.2) has a difference of 8 Da. Thus, we were 
able to target these pairs of precursor and product ions without interference from each other. 
Representative chromatograms of the LC-MS/MS analysis using the chosen transitions from 
a patient sample are shown in Fig. 1.
Calibration curve, linearity, precision and accuracy
The calibration curves from three consecutive batches using BSA as blank matrix showed an 
overall accuracy of 96.0–107.0% with relative standard deviation (RSD) of no more than 
6.4% (Table 1). The linear range of LG021 was 10.0 nM–500.0 nM. The lower limit of 
quantification was 10.0 nM. The intra- and inter-assay precision and accuracy from three 
consecutive batches using BSA as a blank matrix are shown in Table 2. The intra-assay 
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accuracy is 93.7–111.5% with RSD of 0.7–10.1%. The inter-assay accuracy is 96.0–104.4% 
with RSD of 2.0–11.0%.
Selectivity and matrix effect
Selectivity of lower QCs was determined using BSA as a blank matrix, yielding an accuracy 
of 100.0% with a relative standard deviation of 0.0% (Supplemental Table 1). Matrix effect 
of lower QCs was determined using BSA as blank matrix, exhibiting −12.5% for LG021 and 
−12.4% for HG021.
Spike-recovery and stability
Overall recoveries from low, mid, and high QCs using BSA as a blank matrix were 73.5% 
for LG021 and 64.8% for HG021, respectively (Table 3). The results indicate that a 
consistent recovery has been achieved at all three QC levels of the analyte and its internal 
standard. The analyte was stable in BSA under different conditions (Table 4). The accuracy 
and precision of 72-hr processed sample reinjection and three freeze/thaw cycles satisfy the 
±15% criteria. However, the examination of 48-hr room temperature storage stability shows 
the analyte was not stable at room temperature for 48 h.
Clinical samples
The mean ± SE level of GPC1 protein in the 6 control samples was 56.8 ± 13.0 nM (Table 
5). By contrast, prior to cancer resection, the corresponding GPC1 levels in the 3 cancer 
samples and the 3 CP samples were 88.7 ± 15.2 nM and 44.3 ± 9.3 nM, respectively. 
Approximately 24 h following surgery mean ± SE GPC1 levels decreased to 73.3 ± 21.2 nM 
and 33.3 ± 3.2 nM in the PDAC and CP samples, respectively (Table 5). As determined by 
one-way ANOVA, GPC1 levels were not significantly different between normal, PDAC and 
CP samples, pre-resection, or between PDAC and CP post-resection (Table 5). There was 
considerable overlap in exosomal GPC1 levels between normal, CP, and PDAC groups (Fig. 
2). Moreover, the AUC was 0.75 when comparing PDAC and control samples (Supplemental 
Fig. S6), with p = 0.09 and p = 0.13 by paired t-tests, respectively, vs normal control. Thus, 
the predictive value of GPC1 levels for PDAC was fair at best, and clearly below our cutoff 
for excellence (defined as AUC>0.90).
RT-qPCR was next used to determine the levels of specific miRs in exosomes from the 
above samples that included the 6 normal controls, 26 additional PDAC patients (total = 29) 
and 8 additional CP patients (total = 11). The levels of miR-10b, -20a, -21, -30c, -106b, 
-181a, -483, -20, -let7a, and -122 were assayed in exosomes and plasma, since these miRs 
have either been implicated in PDAC or in modulation of cancer cell proliferation and 
migration [24–26,35–41]. Exosomal miR-10b, -20a, -21, -30c, -106b, and -181a were 
present at high levels in PDAC and were low in the CP and normal samples, whereas 
exosomal miR-let7a (which is also known as let7a or let-7a) and miR-122 were lower in 
PDAC samples by comparison with either normal or CP samples, while miR-483 levels were 
similar in all three groups (Table 6 and Fig. 3). Moreover, post-resection, the elevated levels 
of exosomal miR-10b, -20a, -21, -30c, -106b decreased to normal values, but there was only 
a partial decrease in miR-181a levels (Table 6). By contrast, the levels of exosomal miR-
let7a and miR-122 were lower in PDAC than in normal or CP samples (Fig. 3). Moreover, 
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miR-let7a normalized post-resection whereas miR-122 levels increased slightly but 
significantly (p < 0.01) above normal levels (Table 6). Importantly, based on the ROC curves 
(Fig. 4), the AUC for exosomal miR-10b, -21, -30c, -181a, and -let7a revealed that these 
miRs had 100% sensitivity and specificity with respect to their accuracy in distinguishing 
PDAC from normal controls; only miR-106b and -483 failed to have an excellent AUC 
(Table 7). Similar trends for elevated miR levels in PDAC plasma by comparison with 
normal and CP plasma were observed for all 6 miRs (Tables 6 and 7). However, only 
miR-10b and miR-30c had 100% sensitivity and specificity with respect to their accuracy in 
distinguishing PDAC plasma from normal control plasma, and only miR-483 failed to have 
an excellent AUC (Table 7). Moreover, in contrast to exosomal miR-106b, which has an 
AUC of 0.85, plasma miR-106b had an AUC of 0.98, indicating that plasma levels of this 
miR were more sensitive for differentiating PDAC from normal samples than exosomal 
miR-106 levels.
Pre-operatively, PDAC, exosomes were especially numerous in the 85–115 nm range 
(Supplemental Fig. S3A), whereas post-resection their diameter distribution changed to that 
observed in CP and control samples (Supplemental Fig. S3B), suggesting that the high level 
of mid-range exosomes most likely derived from the cancer. However, the vast majority of 
PDAC patients had stage IIB disease (Supplemental Table 2). Therefore, it was not possible 
to assess whether there was a correlation between exosomal miR levels and tumor stage. 
Because CA 19-9 is an FDA-approved PDAC biomarker, its levels were assayed in all 29 
patients (Supplemental Table 2) yielding a sensitivity of 86% with an AUC of 0.92 
(Supplemental Fig. 7). There were variable decreases in CA 19-9 levels post-resection, 
perhaps due to varying clearance rates for this biomarker among patients. Importantly, 8 
patients had normal or slightly elevated CA 19-9 levels (Supplemental Table 2). Based on 
the calculated cutoff values (Table 7) all 8 of these patients had high levels of exosomal and 
plasma miR-10b and -30c, and low levels of exosomal let7a (Supplemental Tables 3–4). 
Moreover, exosomal miR-21 and miR-181a levels were elevated and miR-122 levels were 
low in 7 of these 8 patients, underscoring the potential clinical utility of exosomal miR 
assays.
Discussion
PDAC is most often insidious in onset and its clinical presentation is preceded for a variable 
time period by non-specific symptoms. Consequently, the diagnosis of PDAC is frequently 
delayed and requires the use of CT scans, MRIs, ERCP and endoscopic ultrasonography 
with tissue sampling, each of which is a costly test and has potential risk. Moreover, the 
levels of circulating biomarkers in the blood, most notably CA19-9, have limited sensitivity 
and specificity. Thus, ~14% of the populations may not express CA19-9 and ~25% of PDAC 
patients do not exhibit a rise in CA19-9 [42]. Conversely, CA19-9 levels may be increased in 
patients with CP, and fine needle aspirations of pancreatic lesions may sometimes be 
difficult to interpret due to the presence of CP-like histological changes in PDAC. These 
clinical circumstances could cause confusion regarding the specific diagnosis, an especially 
vexing dilemma since the risk of PDAC is increased ~10 to 16-fold in patients with CP [43]. 
The combination of non-specific symptomatology, absence of specific and sensitive 
screening test, and occasional inconclusive diagnostic tests means that PDAC diagnosis is 
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most often established at an advanced stage when the cancer has either metastasized or has 
invaded major organs, precluding resection [2]. Moreover, PDAC is treatment recalcitrant 
due to intrinsic chemo-resistance of the cancer cells and the intense desmoplasia that 
interferes with efficient drug delivery [2]. Thus, there is an urgent need to develop new 
biomarkers for PDAC that are both sensitive and specific, and that would allow for an earlier 
diagnosis.
Exosomes are membranous extracellular vesicles that are shed by many cell types and that 
range in size from 40 to 120 nM [29,30]. Exosomes carry RNAs, miRNAs, DNA, lipids, and 
proteins, and their internalization into cells results in the uptake of HSPGs, including GPC1, 
by the exosomes [14]. Given the overexpression of GPC1 in PDAC [11] and the report that 
exosomal GPC1 may serve as a biomarker for early PDAC detection [15], we used LC-
MS/MS to establish a highly sensitive and reproducible assay for GPC1, allowing for a 
quantitative analysis of GPC1 levels. We determined that GPC1 protein levels in exosomes 
from PDAC patients tend to be slightly higher than in exosomes from individual without 
pancreatic disease and from CP patients, but these differences are not statistically different. 
Although the number of subjects in our study in each of these categories is small, the 
abundance of GPC1 protein in normal and CP-derived exosomes, and the persistent presence 
of GPC1 protein in exosomes following PDAC resection make it unlikely that this assay, 
which measures the levels of the core protein of GPC1, could serve as a test for early PDAC 
diagnosis or for differentiating between PDAC and CP.
GPC1 is decorated with three glycosaminoglycans (GAGs) side chains, and it is conceivable 
that glycanation of these side chains is qualitatively different in PDAC by comparison with 
CP. Such differences may arise, for example, as a result of the addition of chondroitin sulfate 
instead of heparan sulfate (HS) to the GAGs, or as a result of altered expression of sulfatases 
and sulfotransferases, leading to HS modifications [44]. Indeed, cancer cells can exhibit 
aberrant glycan structure and glycosylation, which can lead to the generation of cancer-
specific epitopes. It is therefore conceivable that antibodies could be generated that 
recognize cancer-specific GAGs on GPC1, which could be used to establish a PDAC-
specific test using exosomes.
Numerous miRs are overexpressed in PDAC, including miR-10b, -20a, -21, -30c, -106b, 
-196a, -196b, -203, -155, -205, -210, -221, -222, -223, -486, -744, and 17-5p [24–26,35–41]. 
Some of these miRs are present at high levels in the plasma and serum of patients with 
PDAC [26,41]. By contrast, certain miRs, such as let7a and miR-122, are tumor suppressor 
miRs that may be underexpressed in cancer [19]. In the present study we demonstrated that 
high exosomal levels of miR-10b, -21, -30c, and -181a and low let7a readily differentiate 
PDAC from normal control and CP samples. By contrast to GPC1, the levels of the elevated 
exosomal miRs declined to normal values within 24 h following PDAC resection, suggesting 
that these miR-rich exosomes originated in the cancers. This conclusion is supported by our 
finding that at 24 h PDAC post-resection, there was a concomitant normalization in the 
excessive number of exosomes whose diameter ranged from 85 to 105 nm that was only 
observed in the PDAC samples, and by reports that exosomes clear rapidly from the 
circulation [45,46]. Importantly, all 29 PDAC cases exhibited high levels of exosomal 
miR-10b and miR-30c, and with the exception of one plasma sample for miR-30c, the 
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corresponding plasma samples were also elevated. Taken together, our findings indicate that 
an exosomal miR signature consisting of elevated levels of miR-10b, -21, -30c, -181a, and 
low let7a is diagnostic for PDAC when used in conjunction with an appropriate clinical 
evaluation, and yields a clear distinction between PDAC and CP.
Both miR-10b and miR-21 have important roles in PDAC [24,25], and miR-10b has been 
shown to downregulate TIP30 and thereby to enhance epidermal growth factor receptor 
(EGFR) signaling [47,48]. EGFR and heparin-binding epidermal growth factor-like growth 
factor (HB-EGF) are crucial for KRAS-driven oncogenesis in PDAC [49–51], and these 
pathways are enhanced by miR-10b. Therefore, the abundance of plasma and exosomal 
miR-10b and miR-21 documented in the present study and miR-10b’s ability to promote 
EGFR-mediated proliferation, invasion, and EGFR-transforming growth factor–beta 
interactions that facilitate epithelial to mesenchymal transition [48] raise the possibility that 
exosomal miR-10b and miR-21 combine to exert a crucial role in PDAC pathobiology. Such 
deleterious actions may be further enhanced by exosomal GPC1, given the important role of 
GPC1 in PCCs, where it facilitates the ability of HBGFs to enhance proliferation and 
invasion [11–13].
Due to the limited number of PDAC cases in the present study it is not possible to establish a 
training and validation cohort. Future studies with a larger number of PDAC and control 
samples are necessary to assess the true sensitivity and specificity of this exosomal miR 
signature. Nonetheless, our findings raise the possibility that our exosomal miR signature 
could be expanded to include other miRs that are elevated in PDAC-derived exosomes as 
well as miRs that are preferentially elevated in plasma over exosomes, as in the case of 
miR-106b. Such a combined exosome and plasma signature could lead to the development 
of sensitive and specific biomarkers for early PDAC diagnosis and for monitoring PDAC 
recurrence following resection.
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ANOVA Analysis of variance
BSA Bovine serum albumin
CP Chronic pancreatitis
ERCP Endoscopic retrograde cholangiopancreatography
GAG Glycosaminoglycan
GPC1 Glypican-1
HPLC High performance liquid chromatography
HSPG Heparan sulfate proteoglycans
IS Internal standard
LC Liquid chromatography
miR MicroRNA
MRM Multiple reaction monitoring
MS/MS Tandem mass spectrometry
PBS Phosphate buffered saline
PDAC Pancreatic ductal adenocarcinoma
QC Quality control
RSD Relative standard deviation
RSP Resistive pulse sensing
RT Retention time
sMRM Scheduled multiple reaction monitoring
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Fig. 1. 
Representative chromatograms of the current LC-MS/MS analysis using the chosen 
transitions from a patient sample spiked with internal standards. Peak intensity and elution 
times (min) are shown for authentic analyte (LG021) and internal standard (HG021).
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Fig. 2. 
Dot plot of exosomal glypican-1 levels in normal controls, pancreatic cancer, and chronic 
pancreatitis. Glypican-1 (GPC1) levels were measured by LC-MS/MS using exosomes 
isolated from6 normal controls (circles), 3 patientswith pancreatic cancer (PDAC; squares), 
and 3 patients with chronic pancreatitis (CP; triangles). Pre-surgery (Pre-Sx; solid symbols) 
and post-Sx (open symbols) sampleswere assayed separately. Horizontal lines: mean values. 
There were no significant differences between the three groups, or between the pre- and 
post-surgery samples, either by ANOVA or paired t-tests.
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Fig. 3. 
Dot plots of exosomal miR levels. The levels of exosomal miRs were assayed in normal 
controls, pancreatic cancer (PDAC), and chronic pancreatitis (CP) samples. Using RT-qPCR, 
miR-10b, -21, -30c, -106b, -20a, -181a, -483, -let7a, and -122 were assessed. (A and B) 
Individual normal control values were expressed as fold change from the mean value for 
controls (closed symbols). These values clustered separately from PDAC values (open 
symbols) for miRs which were overexpressed (A) or underexpressed (B) compared to 
respective mean normal values. (C and D) Similarly, CP values (closed symbols) clustered 
separately from PDAC values (open symbols). Horizontal lines represent cutoff values 
generated by ROC statistics.
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Fig. 4. 
Receiver operating characteristic (ROC). The levels of the indicated miRs in pre-surgery 
exosomes from 29 PDAC patients and, separately, from 6 normal controls, were used to 
generate ROC curves for overexpressed (A) and underexpressed (B) miRs.
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Table 3
Recoveries at low, mid and high QC levels for GPC1 and the IS in 1% BSA.
QC levels Statistics GPC1 IS
Low RSD (%)a 21.3/5.6 20.7/6.2
Recovery (%) 50.8 49.3
Mid RSD (%)a 24.0/40.4 23.5/33.3
Recovery (%) 99.3 79.0
High RSD (%)a 31.3/43.3 28.4/41.0
Recovery (%) 70.4 65.9
Overall Recovery (%) 73.5 64.8
a
RSD: RSD of six replicates of extracted QC samples/RSD of three replicates of recovery samples.
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Table 4
Stability of GPC1 at low, mid, and high QC levels in 1% BSA under different conditions.
QC levels Statistics GPC1
72 h 4 °C processed-sample reinjection
n 6
Low RSD (%) 0.0
Accuracy (%) 100.0
n 6
Mid RSD (%) 4.0
Accuracy (%) 101.7
n 6
High RSD (%) 3.3
Accuracy (%) 98.7
Three freeze/thaw matrix stability
n 6
Low RSD (%) 9.8
Accuracy (%) 83.3
n 6
Mid RSD (%) 0.0
Accuracy (%) 90.0
n 6
High RSD (%) 3.6
Accuracy (%) 94.0
48 h room temperature matrix stability
n 6
Low RSD (%) 14.4
Accuracy (%) 56.7
n 6
Mid RSD (%) 8.4
Accuracy (%) 48.3
n 6
High RSD (%) 9.8
Accuracy (%) 50.0
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Table 5
GPC1 levels in human exosomes.
Analysis group GPC1 Levels (nM, mean ± SE)
Normal controls 56.8 ± 13.0
PDAC 88.7 ± 15.2
Pre-surgery
PDAC 73.3 ± 21.2
Post-surgery
CP 44.3 ± 9.3
Pre-surgery
CP 33.3 ± 3.2
Post-surgery
Exosomes were obtained from 6 normal controls, 3 PDAC cases pre- and post-surgery, and 3 CP cases pre- and post-surgery.
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